Table 3.
The prognostic significance of SPARC mRNA levels in patients with CRC revealed by univariate and multivariate COX analysis.
| Parameter | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Disease-specific survival | ||||||
| Age <70 years>70 years | 1,570 | 0,775-3,199 | 0,208 | 1,180 | 0,475-3,000 | 0,716 |
| Stage Early (1-2)Advanced (3) | 2,620 | 1,001-6,894 | 0,0049 | 5,710 | 0,00005-591217 | 0,767 |
| Tumor size T1-2 T3-4 | 1,670 | 0,642-4,364 | 0,291 | 3,760 | 0,853-16,700 | 0,080 |
| Vascular invasion Negative Positive | 2,420 | 1,067-5,496 | 0,034 | 2,050 | 0,772-5,500 | 0,148 |
| Lymphovascular invasion Negative Positive | 1,170 | 0,549-2,507 | 0,679 | 1,130 | 0,398-3,200 | 0,821 |
| Lymphatic metastasis Negative Positive | 2,240 | 0,917-5,502 | 0,228 | 0,040 | 0-5131 | 0,609 |
| SPARC expression <14,74>14,74 | 2,870 | 1,377-6,006 | 0,004 | 6,650 | 2,208-20,100 | 0,0007 |
| Progression-free survival | ||||||
| Age <70 years>70 years | 1,370 | 0,889-2,139 | 0,150 | 1,420 | 0,882-2,290 | 0,148 |
| Stage Early (1-2) Advanced (3) | 0,840 | 0,527-1,340 | 0,467 | 6,920 | 0,003-1773 | 0,493 |
| Tumor size T1-2 T3-4 | 1,310 | 0,758-2,276 | 0,330 | 1,840 | 0,954-3,569 | 0,068 |
| Vascular invasion Negative Positive | 1,610 | 0,962-2,697 | 0,069 | 1,640 | 0,556-2,816 | 0,072 |
| Lymphovascular invasion Negative Positive | 1,250 | 0,793-1978 | 0,333 | 1,480 | 0,844-2,600 | 0,170 |
| Lymphatic metastasis Negative Positive | 0,820 | 0,517-1,315 | 0,118 | 0,090 | 0,003-23,335 | 0,396 |
| SPARC expression <14,52>14,52 | 2,060 | 1,308-3,258 | 0,002 | 1,880 | 1,144-3,120 | 0,001 |